GB0129007D0 - Adjuvanted antigenic meningococcal compositions - Google Patents

Adjuvanted antigenic meningococcal compositions

Info

Publication number
GB0129007D0
GB0129007D0 GBGB0129007.1A GB0129007A GB0129007D0 GB 0129007 D0 GB0129007 D0 GB 0129007D0 GB 0129007 A GB0129007 A GB 0129007A GB 0129007 D0 GB0129007 D0 GB 0129007D0
Authority
GB
United Kingdom
Prior art keywords
adjuvanted
compositions
meningococcal compositions
adjuvanted antigenic
antigenic meningococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0129007.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Priority to GBGB0129007.1A priority Critical patent/GB0129007D0/en
Publication of GB0129007D0 publication Critical patent/GB0129007D0/en
Priority to AT02788442T priority patent/ATE485055T1/de
Priority to EP02788442A priority patent/EP1448230B1/en
Priority to DE60238075T priority patent/DE60238075D1/de
Priority to JP2003548874A priority patent/JP4414226B2/ja
Priority to CA2468935A priority patent/CA2468935C/en
Priority to US10/497,709 priority patent/US20060008476A1/en
Priority to PCT/IB2002/005662 priority patent/WO2003047619A2/en
Priority to APAP/P/2004/003074A priority patent/AP2004003074A0/en
Priority to AU2002353417A priority patent/AU2002353417A1/en
Priority to JP2009096521A priority patent/JP2009155344A/ja
Priority to US12/787,366 priority patent/US20100233205A1/en
Priority to CY20111100056T priority patent/CY1111114T1/el
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0129007.1A 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions Ceased GB0129007D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
AU2002353417A AU2002353417A1 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
US10/497,709 US20060008476A1 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
EP02788442A EP1448230B1 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
DE60238075T DE60238075D1 (de) 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen
JP2003548874A JP4414226B2 (ja) 2001-12-04 2002-12-04 アジュバント化された抗原性髄膜炎菌性組成物
CA2468935A CA2468935C (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
AT02788442T ATE485055T1 (de) 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
APAP/P/2004/003074A AP2004003074A0 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions
JP2009096521A JP2009155344A (ja) 2001-12-04 2009-04-10 アジュバント化された抗原性髄膜炎菌性組成物
US12/787,366 US20100233205A1 (en) 2001-12-04 2010-05-25 Adjuvanted antigenic meningococcal compositions
CY20111100056T CY1111114T1 (el) 2001-12-04 2011-01-18 Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
GB0129007D0 true GB0129007D0 (en) 2002-01-23

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0129007.1A Ceased GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions

Country Status (11)

Country Link
US (2) US20060008476A1 (https=)
EP (1) EP1448230B1 (https=)
JP (2) JP4414226B2 (https=)
AP (1) AP2004003074A0 (https=)
AT (1) ATE485055T1 (https=)
AU (1) AU2002353417A1 (https=)
CA (1) CA2468935C (https=)
CY (1) CY1111114T1 (https=)
DE (1) DE60238075D1 (https=)
GB (1) GB0129007D0 (https=)
WO (1) WO2003047619A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
AU2002346249B2 (en) * 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012059593A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3897706A4 (en) 2018-12-21 2022-11-23 Griffith University COMPOSITIONS, METHODS AND USES FOR INDURING AN IMMUNE RESPONSE
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021067628A2 (en) * 2019-10-01 2021-04-08 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2671261A1 (en) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
EP1047784B2 (en) * 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
PT1117435E (pt) * 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
US20100233205A1 (en) 2010-09-16
AU2002353417A1 (en) 2003-06-17
DE60238075D1 (de) 2010-12-02
CA2468935A1 (en) 2003-06-12
JP4414226B2 (ja) 2010-02-10
AP2004003074A0 (en) 2004-06-30
EP1448230B1 (en) 2010-10-20
ATE485055T1 (de) 2010-11-15
CA2468935C (en) 2013-02-05
WO2003047619A2 (en) 2003-06-12
CY1111114T1 (el) 2015-06-11
EP1448230A2 (en) 2004-08-25
US20060008476A1 (en) 2006-01-12
WO2003047619A3 (en) 2003-10-23
JP2009155344A (ja) 2009-07-16
JP2005511662A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
GB0129007D0 (en) Adjuvanted antigenic meningococcal compositions
HUP0301413A3 (en) Vaccine compositions
IL227966A0 (en) Vaccination kit
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
HUP0302117A3 (en) Vaccine composition
IL188834A0 (en) Novel vaccine composition
GB0020089D0 (en) Vaccine Composition
GB0306611D0 (en) Novel vaccine
GB0024200D0 (en) Component vaccine
HUP0303942A3 (en) Novel vaccine composition
GB0121171D0 (en) Vaccine
GB0126266D0 (en) Anthrax antigenic compositions
ZA200401211B (en) Antigenic compositions
AU2001267541A1 (en) Vaccine composition
GB0027433D0 (en) Vaccine component
GB0006770D0 (en) Vaccine composition
GB0101138D0 (en) Vaccine composition
GB0108363D0 (en) Vaccine composition
GB0100512D0 (en) Vaccine composition
HK1066178A (en) Antigenic compositions
GB0016686D0 (en) Novel vaccine
GB0104538D0 (en) Novel Vaccine
GB0107511D0 (en) Novel vaccine
GB0104542D0 (en) Novel vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)